학술논문
The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use
Document Type
Artikel
Author
Source
The oncologist. 20(2):196-201
Subject
Language
English
English
English
ISSN
1549-490X